Edition:
United States

Profile: Sinovac Biotech Ltd (SVA.O)

SVA.O on Nasdaq

7.07USD
18 Oct 2017
Change (% chg)

-- (--)
Prev Close
$7.07
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
124,169
52-wk High
$7.16
52-wk Low
$4.60

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Company Address

Sinovac Biotech Ltd

39 Shangdi Xi Road, Haidian Dist
BEIJING   BEJ   100085
P: +8610.82890088
F: +8610.62966910

Company Web Links